Xiaobo Yang1,2, You Shang1,2, Shiying Yuan1,2. 1. Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 2. Institute of Anesthesiology and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Abstract
BACKGROUND: Data on the safety and feasibility of pulse oxygen saturation (SpO2) directed oxygen therapy in mainland China are scarce. The aim of this pilot study was to test the feasibility of SpO2 directed oxygen therapy and to calculate sample size base on differences in 28-day mortality rates for a large sample-sized randomized trial. METHODS: This prospective pilot study enrolled 214 adult patients with an expected intensive care unit (ICU) stay of more than 72 hours. Patients were randomized into a low SpO2 group (SpO2 90-95%) or high SpO2 group (SpO2 96-100%). The primary outcome was 28-day mortality. RESULTS: One hundred patients were included in the low SpO2 group, and 114 patients were included in the high SpO2 group. The demographic and baseline characteristics were not different. The time-weighted SpO2 average was significantly lower in the low SpO2 group than in the high SpO2 group [mean ± standard deviation (SD), 95.7%±2.3% vs. 98.2%±1.8%, P<0.001]. Twenty-six patients (26%) in the low SpO2 group died within 28 days after inclusion, while 37 patients (32.5%) in the high SpO2 group died (P=0.301). The time to death within 28 days between the two groups was not different (P=0.284). CONCLUSIONS: SpO2 directed oxygen therapy in critically ill patients was feasible. Our pilot trial necessitates and rationalizes our large-sample multicenter trial. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: Data on the safety and feasibility of pulse oxygen saturation (SpO2) directed oxygen therapy in mainland China are scarce. The aim of this pilot study was to test the feasibility of SpO2 directed oxygen therapy and to calculate sample size base on differences in 28-day mortality rates for a large sample-sized randomized trial. METHODS: This prospective pilot study enrolled 214 adult patients with an expected intensive care unit (ICU) stay of more than 72 hours. Patients were randomized into a low SpO2 group (SpO2 90-95%) or high SpO2 group (SpO2 96-100%). The primary outcome was 28-day mortality. RESULTS: One hundred patients were included in the low SpO2 group, and 114 patients were included in the high SpO2 group. The demographic and baseline characteristics were not different. The time-weighted SpO2 average was significantly lower in the low SpO2 group than in the high SpO2 group [mean ± standard deviation (SD), 95.7%±2.3% vs. 98.2%±1.8%, P<0.001]. Twenty-six patients (26%) in the low SpO2 group died within 28 days after inclusion, while 37 patients (32.5%) in the high SpO2 group died (P=0.301). The time to death within 28 days between the two groups was not different (P=0.284). CONCLUSIONS: SpO2 directed oxygen therapy in critically ill patients was feasible. Our pilot trial necessitates and rationalizes our large-sample multicenter trial. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Dion Stub; Karen Smith; Stephen Bernard; Ziad Nehme; Michael Stephenson; Janet E Bray; Peter Cameron; Bill Barger; Andris H Ellims; Andrew J Taylor; Ian T Meredith; David M Kaye Journal: Circulation Date: 2015-05-22 Impact factor: 29.690
Authors: Robin Hofmann; Stefan K James; Tomas Jernberg; Bertil Lindahl; David Erlinge; Nils Witt; Gabriel Arefalk; Mats Frick; Joakim Alfredsson; Lennart Nilsson; Annica Ravn-Fischer; Elmir Omerovic; Thomas Kellerth; David Sparv; Ulf Ekelund; Rickard Linder; Mattias Ekström; Jörg Lauermann; Urban Haaga; John Pernow; Ollie Östlund; Johan Herlitz; Leif Svensson Journal: N Engl J Med Date: 2017-08-28 Impact factor: 91.245
Authors: Theresa M Olasveengen; Allan R de Caen; Mary E Mancini; Ian K Maconochie; Richard Aickin; Dianne L Atkins; Robert A Berg; Robert M Bingham; Steven C Brooks; Maaret Castrén; Sung Phil Chung; Julie Considine; Thomaz Bittencourt Couto; Raffo Escalante; Raúl J Gazmuri; Anne-Marie Guerguerian; Tetsuo Hatanaka; Rudolph W Koster; Peter J Kudenchuk; Eddy Lang; Swee Han Lim; Bo Løfgren; Peter A Meaney; William H Montgomery; Peter T Morley; Laurie J Morrison; Kevin J Nation; Kee-Chong Ng; Vinay M Nadkarni; Chika Nishiyama; Gabrielle Nuthall; Gene Yong-Kwang Ong; Gavin D Perkins; Amelia G Reis; Giuseppe Ristagno; Tetsuya Sakamoto; Michael R Sayre; Stephen M Schexnayder; Alfredo F Sierra; Eunice M Singletary; Naoki Shimizu; Michael A Smyth; David Stanton; Janice A Tijssen; Andrew Travers; Christian Vaillancourt; Patrick Van de Voorde; Mary Fran Hazinski; Jerry P Nolan Journal: Circulation Date: 2017-11-06 Impact factor: 29.690
Authors: Nariman Sepehrvand; Stefan K James; Dion Stub; Ardavan Khoshnood; Justin A Ezekowitz; Robin Hofmann Journal: Heart Date: 2018-03-29 Impact factor: 5.994
Authors: J Hope Kilgannon; Alan E Jones; Nathan I Shapiro; Mark G Angelos; Barry Milcarek; Krystal Hunter; Joseph E Parrillo; Stephen Trzeciak Journal: JAMA Date: 2010-06-02 Impact factor: 56.272
Authors: Rakshit Panwar; Miranda Hardie; Rinaldo Bellomo; Loïc Barrot; Glenn M Eastwood; Paul J Young; Gilles Capellier; Peter W J Harrigan; Michael Bailey Journal: Am J Respir Crit Care Med Date: 2016-01-01 Impact factor: 21.405
Authors: Thomas Lass Klitgaard; Olav Lilleholt Schjørring; Frederik Mølgaard Nielsen; Christian Sylvest Meyhoff; Marija Barbateskovic; Jørn Wetterslev; Anders Perner; Bodil Steen Rasmussen Journal: J Intensive Care Date: 2021-12-07